ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Targeting protein-protein interactions in the BCL-2 family: opportunities for precision oncology.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apoptosis plays a pivotal role in the biological process that responds to cellular oxidative stress and significantly contributes to cancer pathogenesis, thereby altering the efficacy of modern cytotoxic treatments. The B-cell lymphoma 2 (BCL-2) protein family exhibits both pro-apoptotic and anti-apoptotic activities that regulate the intrinsic apoptotic pathway. BCL-2 family members, including pro-apoptotic and pro-survival proteins, are highly expressed or dysregulated in cancer cells, thereby promoting tumor progression and therapeutic resistance. This review systematically summarizes the structural organization, molecular functions, and therapeutic significance of the BCL-2 family in cancer. Furthermore, we critically discuss the active role of the BCL-2 family in modulating apoptosis and evaluate recent advances in the development of BH3 mimetics (Venetoclax (ABT-199), Navitoclax (ABT-263), Obatoclax (GX15-070)) and other BCL-2-targeted therapies. The review also highlights emerging mechanisms of drug resistance, including compensatory MCL-1 overexpression, and discusses current combination therapeutic strategies to overcome resistance. The available preclinical and clinical evidence denotes the therapeutic potential of the BCL-2 family as a promising target for cancer treatment. The single- and combined therapy with Venetoclax, a selective BCL-2 BH3 mimetic, has demonstrated higher efficacy and improved safety compared with conventional therapies and has been successfully applied across distinct cancer types. Finally, we discuss current challenges, including resistance mechanisms and treatment-related toxicities, and outline future directions focusing on biomarker-guided patient stratification and next-generation BCL-2-targeted therapeutics.
Indexed as
Identifiers
42570165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.